Profile
Dr. Reiser has been the Board Member at Syngenta AG since 2002.
He is currently a Member of the Foreign Policy Committee of the Swiss Popular Party (SVP) and a Director of the HCB Happy Child Birth AG.
Previously, he served as Chairman of ESBATech AG from 2002 to 2004, as Director and Advisor from 1999 to 2001 and President and Chief Executive Officer of Novartis Pharma K.K.
Japan from 1995 to 1999, and as President and Chief Executive Officer of Holvis AG from 1990 to 1995.
He studied law at the University of Zurich and graduated from the University of Geneva with a PhD in political science.
Former positions of Pedro Reiser
| Companies | Position | End |
|---|---|---|
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Chairman | 31/12/2003 |
Holvis AG
 Holvis AG Pulp & PaperProcess Industries Part of Signature Aviation US Topco LLC, Holvis AG is a paper concern. The company is based in Basel, Switzerland. Holvis was acquired by Signature Aviation Ltd., part of Signature Aviation US Topco LLC from June 01, 2021 on June 01, 1995 for $404.89 million. | President | 31/12/1994 |
Training of Pedro Reiser
| University of Zurich | Undergraduate Degree |
| University of Geneva | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
Holvis AG
Holvis AG Pulp & PaperProcess Industries Part of Signature Aviation US Topco LLC, Holvis AG is a paper concern. The company is based in Basel, Switzerland. Holvis was acquired by Signature Aviation Ltd., part of Signature Aviation US Topco LLC from June 01, 2021 on June 01, 1995 for $404.89 million. | Process Industries |
- Stock Market
- Insiders
- Pedro Reiser
